Guideline for the diagnosis and management of myelofibrosis
Reilly JT. et al, (2012), British Journal of Haematology, 158, 453 - 471
PERTURBATION OF FETAL LIVER HAEMATOPOIETIC STEM AND PROGENITOR CELL DEVELOPMENT BY TRISOMY 21
Roy A. et al, (2012), HAEMATOLOGICA, 97, 40 - 41
Improved survival with MEK inhibition in BRAF-mutated melanoma.
Flaherty KT. et al, (2012), N Engl J Med, 367, 107 - 114
Ipilimumab: A novel immunomodulating therapy causing autoimmune hypophysitis: A case report and review
Juszczak A. et al, (2012), European Journal of Endocrinology, 167, 1 - 5
Ipilimumab: a novel immunomodulating therapy causing autoimmune hypophysitis: a case report and review.
Juszczak A. et al, (2012), Eur J Endocrinol, 167, 1 - 5
CLINICAL DIAGNOSTIC IMPLEMENTATION OF AN INNOVATIVE CANCER CARE MODEL BASED ON COMPREHENSIVE MOLECULAR PROFILING OF TUMOUR-NORMAL PAIRS
Kaur K. et al, (2012), ANNALS OF ONCOLOGY, 23, 12 - 13
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial.
Cummings J. et al, (2012), Br J Cancer, 106, 1766 - 1771
Evaluation of cell death mechanisms induced by the vascular disrupting agent OXi4503 during a phase I clinical trial
Cummings J. et al, (2012), British Journal of Cancer, 106, 1766 - 1771
Phase I study to determine the bioavailability and tolerability of a tablet formulation of the PARP inhibitor olaparib in patients with advanced solid tumors: Dose-escalation phase.
Gupta A. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Use of DNA repair proteins translated from biomarker screening to predict overall survival in patients with esophageal cancer treated with oxaliplatin chemotherapy
Sharma RA. et al, (2012), JOURNAL OF CLINICAL ONCOLOGY, 30
Allogeneic Stem Cell Transplantation for Myelofibrosis in 2012
Mclornan DP. et al, (2012), British Journal of Haematology, 157, 413 - 425
In vivo effects of eltrombopag on platelet function in immune thrombocytopenia: no evidence of platelet activation.
Psaila B. et al, (2012), Blood, 119, 4066 - 4072
BYL719, a next generation PI3K alpha specific inhibitor: Preliminary safety, PK, and efficacy results from the first-in-human study
Juric D. et al, (2012), CANCER RESEARCH, 72
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate.
Khan OA. et al, (2012), Br J Cancer, 106
Reply: Metronomic chemotherapy with cyclophosphamide and dexamethasone in patients with metastatic carcinoma of the prostate
Khan OA. et al, (2012), British Journal of Cancer, 106
A study of symptoms described by ovarian cancer survivors.
Stavraka C. et al, (2012), Gynecol Oncol, 125, 59 - 64
Germline activating JAK2-mutation in a family with hereditary thrombocytosis
Mead A. et al, (2012), BRITISH JOURNAL OF HAEMATOLOGY, 157, 21 - 21
Germline JAK2 mutation in a family with hereditary thrombocytosis.
Mead AJ. et al, (2012), N Engl J Med, 366, 967 - 969
Phase I clinical and pharmacokinetic evaluation of the vascular-disrupting agent OXi4503 in patients with advanced solid tumors.
Patterson DM. et al, (2012), Clin Cancer Res, 18, 1415 - 1425